[DE] GUANIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS BINDUNGSPARTNER FÜR 5-HT5-REZEPTOREN [EN] GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS [FR] COMPOSES DE GUANIDINE ET LEUR UTILISATION COMME ELEMENTS DE LIAISON POUR LES RECEPTEURS 5-HT5
[DE] GUANIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS BINDUNGSPARTNER FÜR 5-HT5-REZEPTOREN [EN] GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS [FR] COMPOSES DE GUANIDINE ET LEUR UTILISATION COMME ELEMENTS DE LIAISON POUR LES RECEPTEURS 5-HT5
Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors
申请人:Netz Astrid
公开号:US20070299074A1
公开(公告)日:2007-12-27
The present invention relates to guanidine compounds of the general formula I
corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
申请人:Netz Astrid
公开号:US20110237589A1
公开(公告)日:2011-09-29
The present invention relates to guanidine compounds of the general formula I
corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
申请人:ABBVIE DEUTSCHLAND GMBH & CO. KG
公开号:US20170037016A1
公开(公告)日:2017-02-09
The present invention relates to guanidine compounds of the general formula I
corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.